Other uses of dexrazoxane: savene, the first proven antidote against anthracycline extravasation injuries

Author： Langer Seppo   Jensen Peter   Sehested Maxwell  

Publisher： Humana Press, Inc

ISSN： 1530-7905

Source： Cardiovascular Toxicology, Vol.7, Iss.2, 2007-06, pp. : 151-153

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Extravasation Injuries of Peripheral Veins: A Basis for Litigation?

By Roth Darnell  

Journal of Vascular Access Devices, Vol. 8, Iss. 1, 2003-0 ,pp. : 13-19

Association of University Programs in Health Administration

Access to resources Recommend Favorite

Extravasation Injuries Associated with the Use of Central Vascular Access Devices

By Masoorli Sue  

Journal of Vascular Access Devices, Vol. 8, Iss. 1, 2003-0 ,pp. : 21-23

Association of University Programs in Health Administration

Access to resources Recommend Favorite

Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxia-reoxygenation damage

By Hasinoff Brian  

Cardiovascular Toxicology, Vol. 2, Iss. 2, 2002-06 ,pp. : 111-118

Humana Press, Inc

Access to resources Recommend Favorite

Antioxidant defense against anthracycline cardiotoxicity by metallothionein

By Kang Y.  

Cardiovascular Toxicology, Vol. 7, Iss. 2, 2007-06 ,pp. : 95-100

Humana Press, Inc

Access to resources Recommend Favorite

Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials

By Bast Aalt   Haenen Guido   Bruynzeel Anna   Vijgh Wim  

Cardiovascular Toxicology, Vol. 7, Iss. 2, 2007-06 ,pp. : 154-159

Humana Press, Inc

Access to resources Recommend Favorite